Macrophage-tumor crosstalk: Role of TAMR tyrosine kinase receptors and of their ligands

Cellular and Molecular Life Sciences

Volumn 69, Issue 9, 2012, Pages 1391-1414

  Schmidt, Thomas ^a   Ben Batalla, Isabel ^b   Schultze, Alexander ^b   Loges, Sonja ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Cancer; Gas6; Inflammation; TAM (Tumor associated macrophages); TAMR (Tyro3, Axl, Mer receptors); Tumor macrophage crosstalk

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; ANTISENSE OLIGONUCLEOTIDE; ARGINASE 1; CARBOPLATIN; CD163 ANTIGEN; CD68 ANTIGEN; COLONY STIMULATING FACTOR 1; CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GROWTH ARREST SPECIFIC PROTEIN 6; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 23; INTERLEUKIN 6; NEUTRALIZING ANTIBODY; R 428; RECEPTOR; STAT3 PROTEIN; STAT6 PROTEIN; STROMAL CELL DERIVED FACTOR 1; TAXANE DERIVATIVE; TEMOZOLOMIDE; THYMIDINE PHOSPHORYLASE; TYRO3 AXL MER RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; GROWTH ARREST-SPECIFIC PROTEIN 6; LIGAND; PROTEIN S; PROTEIN TYROSINE KINASE; SIGNAL PEPTIDE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST CARCINOMA; CANCER CELL; CANCER SURVIVAL; CARCINOGENESIS; CELL INTERACTION; CELL PROLIFERATION; COLON CANCER; CYTOKINE RELEASE; DRUG RESPONSE; DRUG SENSITIVITY; ENDOTHELIUM CELL; FIBROBLAST; GLIOMA; HUMAN; INFLAMMATION; KIDNEY CANCER; LUNG CANCER; MACROPHAGE; MACROPHAGE FUNCTION; MELANOMA; METASTASIS; METASTASIS INHIBITION; NEOPLASM; NONHUMAN; OVARY CANCER; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SKIN CANCER; STOMACH CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR VASCULARIZATION; UTERUS CANCER; BIOLOGICAL MODEL; CLASSIFICATION; FEMALE; IMMUNOLOGY; LEUKOCYTE; MALE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TUMOR MICROENVIRONMENT;

ENDOTHELIAL CELLS; FEMALE; FIBROBLASTS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKOCYTES; LIGANDS; MACROPHAGES; MALE; MODELS, BIOLOGICAL; NEOPLASMS; PROGNOSIS; PROTEIN S; RECEPTOR PROTEIN-TYROSINE KINASES; TUMOR MICROENVIRONMENT;

EID: 84862308455     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-011-0863-7     Document Type: Review

References (226)

1. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57-70 S0092-8674(00)81683-9[pii] (Pubitemid 30046295)
2. Allen M, Louise Jones J (2011) Jekyll and Hyde: the role of the microenvironment on the progression ofcancer. J Pathol 223(2): 162-176. doi:10.1002/path.2803
3. Joyce JA, Pollard JW (2009) Microenvironmental regulation of metastasis. Nat Rev Cancer 9(4):239-252. doi:10.1038/nrc2618
4. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454(7203):436-444. doi:10.1038/ nature07205
5. Tlsty TD, Coussens LM (2006) Tumor stroma and regulation of cancer development. Annu Rev Pathol 1:119-150. doi:10.1146/ annurev.pathol.1.110304. 100224
6. Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6):883-899. doi:10.1016/ j.cell.2010.01.025
7. Qian BZ, Pollard JW (2010) Macrophage diversity enhances tumor progression and metastasis. Cell 141(1):39-51. doi: 10.1016/j.cell.2010.03.014
8. Balkwill F, Charles KA, Mantovani A (2005) Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7(3):211-217. doi:10.1016/j.ccr. 2005.02.013 (Pubitemid 40568680)
9. De Clerck YA, Mercurio AM, Stack MS, Chapman HA, Zutter MM, Muschel RJ, Raz A, Matrisian LM, Sloane BF, Noel A, Hendrix MJ, Coussens L, Padarathsingh M (2004) Proteases, extracellular matrix, and cancer: a workshop of the path B study section. Am J Pathol 164(4):1131-1139. doi:10.1016/S0002-9440(10)63200-2 (Pubitemid 38387779)
10. Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473(7347):298-307. doi: 10.1038/nature10144
11. Folkman J(1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21):1182-1186. doi:10.1056/NEJM1971111 82852108
12. Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358(19):2039-2049. doi:10.1056/NEJMra0706596 (Pubitemid 351656458)
13. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS, Albelda SM (2009) Polarization of tumor-associ-ated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 16(3):183-194. doi:10.1016/j.ccr.2009.06. 017
14. Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, Chorianopoulos E, Liesenborghs L, Koch M, De Mol M, Autiero M, Wyns S, Plaisance S, Moons L, van Rooijen N, Giacca M, Stassen JM, Dewerchin M, Collen D, Carmeliet P (2007) Anti-Pl GF inhibits growth of VEGF(R)-inhibitor-resis-tant tumors without affecting healthy vessels. Cell 131(3): 463-475 (Pubitemid 350007692)
15. Shiai F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, Fuh G, Gerber HP, Ferrara N (2007) Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+ Gr1+ myeloid cells. Nat Biotechnol 25(8):911-920. doi:10.1038/nbt1323 (Pubitemid 47236916)
16. Bissell MJ, Hines WC (2011) Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 17(3):320-329. doi:10.1038/nm.2328
17. Tiwari M (2010) From tumor immunology to cancer immuno-therapy: miles to go. J Cancer Res Ther 6(4):427-431. doi: 10.4103/0973-1482.77071
18. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30(7):1073-1081. doi:10.1093/carcin/bgp127
19. de Visser KE, Eichten A, Coussens LM (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6(1):24-37. doi:10.1038/nrc1782 (Pubitemid 43053650)
20. Mantovani A, Sica A (2010) Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 22(2):231-237. doi:10.1016/j.coi.2010.01.009
21. Pollard JW (2009) Trophic macrophages in development and disease. Nat Rev Immunol 9(4):259-270. doi:10.1038/nri2528
22. Condeelis J, Pollard JW (2006) Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124(2):263-266. doi:10.1016/j.cell.2006.01.007 (Pubitemid 43121975)
23. Biswas SK, Mantovani A (2010) Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 11(10):889-896. doi:10.1038/ni.1937
24. Gordon S, Taylor PR (2005) Monocyte and macrophage heter-ogeneity. Nat Rev Immunol 5(12):953-964. doi:10.1038/nri 1733 (Pubitemid 41746764)
25. Hussain SP, Hofseth LJ, Harris CC (2003) Radical causes of cancer. Nat Rev Cancer 3(4):276-285. doi:10.1038/nrc1046 (Pubitemid 37328863)
26. Jeannin P, Duluc D, Delneste Y (2011) IL-6 and leukemia-inhibitory factor are involved in the generation of tumor-asso-ciated macrophage: regulation by IFN-gamma. Immunotherapy 3(4 Suppl):23-26. doi:10.2217/imt.11.30
27. Heusinkveld M, van Steenwijk PJ, Goedemans R, Ram-wadhdoebe TH, Gorter A, Welters MJ, van Hall T, van der Burg SH (2011) M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J Immunol 187(3):1157-1165. doi: 10.4049/jimmunol.1100889
28. Hagemann T, Biswas SK, Lawrence T, Sica A, Lewis CE (2009) Regulation of macrophage function in tumors: the multifaceted role of NF-kappa B. Blood 113(14):3139-3146. doi:10.1182/ blood-2008-12-172825
29. Sica A, Bronte V (2007) Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 117(5):1155-1166. doi:10.1172/JCI31422 (Pubitemid 46718400)
30. Jiang H, Harris MB, Rothman P (2000) IL-4/IL-13 signaling beyond JAK/STAT. J Allergy Clin Immunol 105(6 Pt 1): 1063-1070 S0091674900452255[pii]
31. Donnelly RP, Dickensheets H, Finbloom DS (1999) The inter-leukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes. J Interferon Cytokine Res 19(6):563-573. doi:10.1089/107999099313695 (Pubitemid 29331308)
32. Martinez FO, Gordon S, Locati M, Mantovani A (2006) Tran-scriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol 177(10):7303-7311 177/10/ 7303[pii] (Pubitemid 44715100)
33. Mosser DM, Edwards JP (2008) Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8(12):958-969. doi: 10.1038/nri2448
34. Pettersen JS, Fuentes-Duculan J, Suarez-Farinas M, Pierson KC, Pitts-Kiefer A, Fan L, Belkin DA, Wang CQ, Bhuvanendran S, Johnson-Huang LM, Bluth MJ, Krueger JG, Lowes MA, Carucci JA (2011) Tumor-associated macrophages in the cutaneous SCC microenvironment are heterogeneously activated. J Invest Der-matol 131(6):1322-1330. doi:10.103/jid.2011.9
35. Rigo A, Gottardi M, Zamo A, Mauri P, Bonifacio M, Krampera M, Damiani E, Pizzolo G, Vinante F (2010) Macrophages may promote cancer growth via a GM-CSF/HB-EGF paracrine loop that is enhanced by CXCL12. Mol Cancer 9:273. doi:10.1186/ 1476-4598-9-273
36. Movahedi K, Laoui D, Gysemans C, Baeten M, Stange G, Van den Bossche J, Mack M, Pipeleers D, In't Veld P, De Baetselier P, Van Ginderachter JA (2010) Different tumor microenviron-ments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res 70(14): 5728-5739. doi:10.1158/0008-5472.CAN-09-4672
37. Hamilton JA (2008) Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 8(7):533-544. doi: 10.1038/nri2356 (Pubitemid 351913679)
38. Bolat F, Kayaselcuk F, Nursal TZ, Yagmurdur MC, Bal N, Demirhan B (2006) Microvessel density, VEGF expression, and tumor-associated macrophages in breast tumors: correlations with prognostic parameters. J Exp Clin Cancer Res 25(3): 365-372 (Pubitemid 44763728)
39. Lee CH, Espinosa I, Vrijaldenhoven S, Subramanian S, Mont-gomery KD, Zhu S, Marinelli RJ, Peterse JL, Poulin N, Nielsen TO, West RB, Gilks CB, van de Rijn M (2008) Prognostic significance of macrophage infiltration in leiomyosarcomas. Clin Cancer Res 14(5):1423-1430. doi:10.1158/1078-0432.CCR-07- 1712 (Pubitemid 351413925)
40. Ohno S, Inagawa H, Dhar DK, Fujii T, Ueda S, Tachibana M, Ohno Y, Suzuki N, Inoue M, Soma G, Nagasue N (2005) Role of tumor-associated macrophages (TAM) in advanced gastric carcinoma: the impact on Fas L-mediated counterattack. Anti-cancer Res 25(1B):463-470 (Pubitemid 40470051)
41. Ohno S, Inagawa H, Dhar DK, Fujii T, Ueda S, Tachibana M, Suzuki N, Inoue M, Soma G, Nagasue N (2003) The degree of macrophage infiltration into the cancer cell nest is a significant predictor of survival in gastric cancer patients. Anticancer Res 23(6D):5015-5022 (Pubitemid 38182119)
42. Jensen TO, Schmidt H, Moller HJ, Hoyer M, Maniecki MB, Sjoegren P, Christensen IJ, Steiniche T (2009) Macrophage markers in serum and tumor have prognostic impact in Ameri-can Joint Committee on Cancer stage I/II melanoma. J Clin Oncol 27(20):3330-3337. doi:10.1200/JCO.2008.19.9919
43. Soeda S, Nakamura N, Ozeki T, Nishiyama H, Hojo H, Yamada H, Abe M, Sato A (2008) Tumor-associated macrophages cor-relate with vascular space invasion and myometrial invasion in endometrial carcinoma. Gynecol Oncol 109(1):122-128. doi: 10.1016/j.ygyno.2007.12.033
44. Hsu HP, Shan YS, Lai MD, Lin PW (2010) Osteopontin-positive infiltrating tumor-associated macrophages in bulky ampullary cancer predict survival. Cancer Biol Ther 10(2):144-154
45. Tanaka Y, Kobayashi H, Suzuki M, Kanayama N, Terao T (2002) Thymidine phosphorylase expression in tumor-infiltrat-ing macrophages may be correlated with poor prognosis in uterine endometrial cancer. Hum Pathol 33(11):1105-1113. doi: 10.1053/hupa.2002.129203S0046817702001636 (Pubitemid 35416708)
46. Wang R, Lu M, Zhang J, Chen S, Luo X, Qin Y, Chen H (2011) Increased IL-10 m RNA expression in tumor-associated macro-phage correlated with late stage of lung cancer. J Exp Clin Cancer Res 30:62. doi:10.1186/1756-9966-30-62
47. Bronkhorst IH, Ly LV, Jordanova ES, Vrolijk J, Versluis M, Luyten GP, Jager MJ (2011) Detection of M2-macrophages in uveal melanoma and relation with survival. Invest Ophthalmol Vis Sci 52(2):643-650. doi:10.1167/iovs.10-5979
48. Hasita H, Komohara Y, Okabe H, Masuda T, Ohnishi K, Lei XF, Beppu T, Baba H, Takeya M (2010) Significance of alterna-tively activated macrophages in patients with intrahepatic cholangiocarcinoma. Cancer Sci 101(8):1913-1919. doi: 10.1111/j.1349-7006.2010.01614.x
49. Ma J, Liu L, Che G, Yu N, Dai F, You Z (2010) The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer 10:112. doi:10.1186/1471-2407-10-112
50. Ohri CM, Shikotra A, Green RH, Waller DA, Bradding P (2009) Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur Respir J 33(1):118-126. doi:10.1183/09031936.00065708
51. Markosyan N, Chen E, Ndong V, Yao Y, Sterner CJ, Chodosh LA, Lawson JA, Fitzgerald GA, Smyth EM (2011) Deletion of cyclooxygenase 2 in mouse mammary epithelial cells delays breast cancer onset through augmentation of type 1 immune responses in tumors. Carcinogenesis 32(10):1441-1449. doi: 10.1093/carcin/bgr134
52. Rolny C, Mazzone M, Tugues S, Laoui D, Johansson I, Coulon C, Squadrito ML, Segura I, Li X, Knevels E, Costa S, Vinckier S, Dresselaer T, Akerud P, De Mol M, Salomaki H, Phillipson M, Wyns S, Larsson E, Buysschaert I, Botling J, Himmelreich U, Van Ginderachter JA, De Palma M, Dewerchin M, Claesson-Welsh L, Carmeliet P (2011) HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of Pl GF. Cancer Cell 19(1):31-44. doi:10.1016/j.ccr.2010.11.009
53. Sanchez-Martin L, Estecha A, Samaniego R, Sanchez-Ramon S, Vega MA, Sanchez-Mateos P (2011) The chemokine CXCL12 regulates monocyte-macrophage differentiation and RUNX3 expression. Blood 117(1):88-97. doi:10.1182/blood- 2009-12-258186
54. Deng L, Zhou JF, Sellers RS, Li JF, Nguyen AV, Wang Y, Orlofsky A, Liu Q, Hume DA, Pollard JW, Augenlicht L, Lin EY (2010) A novel mouse model of inflammatory bowel disease links mammalian target of rapamycin-dependent hyperproliferation of colonic epithelium to inflammation-asso- ciatedtumorigenesis. Am JPathol 176(2):952-967. doi:10.2353/ ajpath.2010.090622
55. Karin M, Greten FR (2005) NF-kappa B: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5(10):749-759. doi:10.1038/nri1703 (Pubitemid 41400849)
56. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118(3):285-296. doi:10.1016/j.cell.2004.07. 013S0092867 404006713 (Pubitemid 39061110)
57. Maeda S, Kamata H, Luo JL, Leffert H, Karin M (2005) IKKbeta couples hepatocyte death to cytokine-driven compensatory pro-liferation that promotes chemical hepatocarcinogenesis. Cell 121(7):977-990. doi:10.1016/j.cell.2005.04. 014 (Pubitemid 40884391)
58. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y (2004) NF-kappa B functions as a tumour promoter in inflam-mation-associated cancer. Nature 431(7007):461-466. doi: 10.1038/nature02924 (Pubitemid 39329586)
59. Arnott CH, Scott KA, Moore RJ, Robinson SC, Thompson RG, Balkwill FR (2004) Expression ofboth TNF-alpha receptor sub-types is essential for optimal skin tumour development. Oncogene 23(10):1902-1910. doi:10.1038/sj.onc. 12073171207317 (Pubitemid 38445416)
60. Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, Holdsworth H, Turner L, Rollins B, Pasparakis M, Kollias G, Balkwill F (1999) Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 5(7):828-831. doi: 10.1038/10552 (Pubitemid 29318619)
61. Balkwill F (2009) Tumour necrosis factor and cancer. Nat Rev Cancer 9(5):361-371. doi:10.1038/nrc2628
62. Oguma K, Oshima H, Aoki M, Uchio R, Naka K, Nakamura S, Hirao A, Saya H, Taketo MM, Oshima M (2008) Activated macrophages promote Wnt signalling through tumour necrosis factor-alpha in gastric tumour cells. EMBO J 27(12):1671-1681. doi:10.1038/emboj.2008.105
63. Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S, Oshima M, Fujii C, Mukaida N (2008) Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 118(2):560-570. doi:10.1172/ JCI32453 (Pubitemid 351206546)
64. Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T, Nebelsiek T, Lundgren-May T, Canli O, Schwitalla S, Matthews V, Schmid RM, Kirchner T, Arkan MC, Ernst M, Greten FR (2009) gp130-mediated Stat3 activation in entero-cytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 15(2):91-102. doi:10.1016/j.ccr. 2009.01.002
65. Yu H, Kortylewski M, Pardoll D (2007) Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenviron-ment. Nat Rev Immunol 7(1):41-51. doi:10.1038/nri1995 (Pubitemid 46020826)
66. Karin M, Lawrence T, Nizet V (2006) Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 124(4):823-835. doi:10.1016/j.cell.2006.02.016 (Pubitemid 43261455)
67. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M (2007) Gender disparity in liver cancer due to sex differences in My D88-dependent IL-6 production. Science 317(5834):121-124. doi: 10.1126/science.1140485 (Pubitemid 47056470)
68. Yi L, Xiao H, Xu M, Ye X, Hu J, Li F, Li M, Luo C, Yu S, Bian X, Feng H (2011) Glioma-initiating cells: a predominant role in microglia/macrophages tropism to glioma. J Neuroimmunol 232(1-2):75-82. doi:10.1016/j.jneuroim.2010. 10.011
69. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23(11):549-555 S1471490602023025[pii] (Pubitemid 35223554)
70. Biswas SK, Gangi L, Paul S, Schioppa T, Saccani A, Sironi M, Bottazzi B, Doni A, Vincenzo B, Pasqualini F, Vago L, Nebu-loni M, Mantovani A, Sica A (2006) A distinct and unique transcriptional program expressed by tumor-associated macro-phages (defective NF-kappa B and enhanced IRF-3/STAT1 activation). Blood 107(5):2112-2122. doi:10.1182/blood-2005-01-0428 (Pubitemid 43289397)
71. Porta C, Rimoldi M, Raes G, Brys L, Ghezzi P, Di Liberto D, Dieli F, Ghisletti S, Natoli G, De Baetselier P, Mantovani A, Sica A (2009) Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor kappa B. Proc Natl Acad Sci U S A 106(35):14978-14983. doi:10.1073/pnas.0809784106
72. Saccani A, Schioppa T, Porta C, Biswas SK, Nebuloni M, Vago L, Bottazzi B, Colombo MP, Mantovani A, Sica A (2006) p50 nuclear factor-kappa B overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res 66(23):11432-11440. doi:10.1158/0008-5472.CAN-06-1867 (Pubitemid 46009975)
73. Sica A, Saccani A, Bottazzi B, Polentarutti N, Vecchi A, van Damme J, Mantovani A (2000) Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J Immunol 164(2):762-767 ji-v164n2p762[pii] (Pubitemid 30043699)
74. Gocheva V, Wang HW, Gadea BB, Shree T, Hunter KE, Garfall AL, Berman T, Joyce JA (2010) IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev 24(3):241-255. doi:10.1101/ gad.1874010
75. Kubota Y, Takubo K, Shimizu T, Ohno H, Kishi K, Shibuya M, Saya H, Suda T (2009) M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J Exp Med 206(5):1089-1102. doi:10.1084/jem.20081605
76. Lin EY, Nguyen AV, Russell RG, Pollard JW (2001) Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 193(6):727-740
77. Abraham D, Zins K, Sioud M, Lucas T, Schafer R, Stanley ER, Aharinejad S (2010) Stromal cell-derived CSF-1 blockade pro-longs xenograft survival of CSF-1-negative neuroblastoma. Int J Cancer 126(6):1339-1352. doi:10.1002/ijc.24859
78. Aharinejad S, Sioud M, Lucas T, Abraham D (2009) Targeting stromal-cancer cell interactions with si RNAs. Methods Mol Biol 487:243-266
79. Loges S, Schmidt T, Carmeliet P (2009) "Antimyeloangiogen-ic" therapy for cancer by inhibiting Pl GF. Clin Cancer Res 15(11):3648-3653. doi:10.1158/1078-0432.CCR-08-2276
80. Van de Veire S, Stalmans I, Heindryckx F, Oura H, Tijeras-Raballand A, Schmidt T, Loges S, Albrecht I, Jonckx B, Vinckier S, Van Steenkiste C, Tugues S, Rolny C, De Mol M, Dettori D, Hainaud P, Coenegrachts L, Contreres JO, Van Bergen T, Cuervo H, Xiao WH, Le Henaff C, Buysschaert I, Kharabi Masouleh B, Geerts A, Schomber T, Bonnin P, Lambert V, Haustraete J, Zacchigna S, Rakic JM, Jimenez W, Noel A, Giacca M, Colle I, Foidart JM, Tobelem G, Morales-Ruiz M, Vilar J, Maxwell P, Vinores SA, Carmeliet G, Dewerchin M, Claesson-Welsh L, Dupuy E, Van Vlierberghe H, Christofori G, Mazzone M, Detmar M, Collen D, Carmeliet P (2010) Further pharmacological and genetic evidence for the efficacy of Pl GF inhibition in cancer and eye disease. Cell 141(1):178-190. doi: 10.1016/j.cell.2010.02.039
81. Wyckoff J, Wang W, Lin EY, Wang Y, Pixley F, Stanley ER, Graf T, Pollard JW, Segall J, Condeelis J (2004) A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res 64(19):7022-7029. doi:10.1158/0008-5472.CAN-04-1449 (Pubitemid 39331012)
82. Wyckoff JB, Wang Y, Lin EY, Li JF, Goswami S, Stanley ER, Segall JE, Pollard JW, Condeelis J (2007) Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res 67(6):2649-2656. doi:10.1158/0008-5472. CAN-06-1823 (Pubitemid 46548952)
83. Green CE, Liu T, Montel V, Lester RD, Subramaniam S, Gonias SL, Klemke RL (2009) Chemoattractant signaling between tumor cells and macrophages regulates cancer cell migration, metastasis and neovascularization. PLo S One 4(8):e6713. doi: 10.1371/journal.pone.0006713
84. De Nardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N, Coussens LM (2009) CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumorproperties ofmacrophages. Cancer Cell 16(2):91-102. doi:10.1016/j.ccr.2009.06.018
85. Franovic A, Gunaratnam L, Smith K, Robert I, Patten D, Lee S (2007) Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overex-pression in human cancer. Proc Natl Acad Sci US A 104(32): 13092-13097. doi:10.1073/pnas.0702387104 (Pubitemid 351737598)
86. Imtiyaz HZ, Williams EP, Hickey MM, Patel SA, Durham AC, Yuan LJ, Hammond R, Gimotty PA, Keith B, Simon MC (2010) Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation. J Clin Invest 120(8):2699-2714. doi:10.1172/JCI39506
87. Ojalvo LS, Whittaker CA, Condeelis JS, Pollard JW (2010) Gene expression analysis of macrophages that facilitate tumor invasion supports a role for Wnt-signaling in mediating their activity in primary mammary tumors. J Immunol 184(2): 702-712. doi:10.4049/jimmunol.0902360
88. Pucci F, Venneri MA, Biziato D, Nonis A, Moi D, Sica A, Di Serio C, Naldini L, De Palma M (2009) A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing mono-cytes, blood "resident" monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood 114(4):901-914. doi:10.1182/blood-2009-01-200931
89. Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, Qian H, Xue XN, Pollard JW (2006) Macrophages regulate the angiogenic switch in a mouse model ofbreast cancer. Cancer Res 66(23):11238-11246. doi:10.1158/0008-5472.CAN-06- 1278 (Pubitemid 46009952)
90. Luo YP, Zhou H, Krueger J, Kaplan C, Liao D, Markowitz D, Liu C, Chen T, Chuang TH, Xiang R, Reisfeld RA (2010) The role of proto-oncogene Fra-1 in remodeling the tumor micro-environment in support of breast tumor cell invasion and progression. Oncogene 29(5):662-673. doi:10.1038/onc.2009. 308
91. Takanami I, Takeuchi K, Kodaira S (1999) Tumor-associated macrophage infiltration in pulmonary adenocarcinoma: associ-ation with angiogenesis and poor prognosis. Oncology 57(2): 138-142 (Pubitemid 29385492)
92. Murri AM, Hilmy M, Bell J, Wilson C, Mc Nicol AM, Lannigan A, Doughty JC, Mc Millan DC (2008) The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic and macrophage infiltration, microvessel density and survival in patients with primary operable breast cancer. Br J Cancer99(7):1013-1019. doi:10.1038/sj.bjc.6604667
93. Fraisl P, Mazzone M, Schmidt T, Carmeliet P (2009) Regulation of angiogenesis by oxygen and metabolism. Dev Cell 16(2): 167-179. doi:10.1016/j.devcel.2009.01.003
94. Murdoch C, Muthana M, Coffelt SB, Lewis CE (2008) The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 8(8):618-631
95. Carmeliet P, Jain RK (2011) Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 10(6):417-427. doi:10.1038/nrd3455
96. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706): 58-62 (Pubitemid 40093472)
97. De Bock K, Cauwenberghs S, Carmeliet P (2011) Vessel ab-normalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications. Curr Opin Genet Dev 21(1):73-79. doi:10.1016/j.gde.2010.10.008
98. Du R, Lu KV, Petritsch C, Liu P, Ganss R, Passegue E, Song H, Vandenberg S, Johnson RS, Werb Z, Bergers G (2008) HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13(3):206-220. doi:10.1016/j.ccr.2008.01. 034 (Pubitemid 351318372)
99. De Palma M, Venneri MA, Galli R, Sergi Sergi L, Politi LS, Sampaolesi M, Naldini L (2005) Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progeni-tors. Cancer Cell 8(3):211-226 (Pubitemid 41317592)
100. Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, Berti A, Politi LS, Gentner B, Brown JL, Naldini L, De Palma M (2011) Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 19(4):512-526. doi: 10.1016/j.ccr.2011.02.005
101. Fantin A, Vieira JM, Gestri G, Denti L, Schwarz Q, Prykhozhij S, Peri F, Wilson SW, Ruhrberg C (2010) Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction. Blood 116(5):829-840. doi:10.1182/blood-2009-12-257832
102. Schmidt T, Carmeliet P (2010) Blood-vessel formation: bridges that guide and unite. Nature 465(7299):697-699. doi:10.1038/ 465697a
103. Baluk P, Tammela T, Ator E, Lyubynska N, Achen MG, Hicklin DJ, Jeltsch M, Petrova TV, Pytowski B, Stacker SA, Yla-Hert-tuala S, Jackson DG, Alitalo K, Mc Donald DM (2005) Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J Clin Invest 115(2):247-257. doi: 10.1172/JCI22037 (Pubitemid 40385467)
104. Jeon BH, Jang C, Han J, Kataru RP, Piao L, Jung K, Cha HJ, Schwendener RA, Jang KY, Kim KS, Alitalo K, Koh GY (2008) Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b+ macrophages in advanced ovarian cancer. Cancer Res 68(4):1100-1109. doi: 10.1158/0008-5472.CAN-07-2572 (Pubitemid 351272228)
105. Moussai D, Mitsui H, Pettersen JS, Pierson KC, Shah KR, Su-arez-Farinas M, Cardinale IR, Bluth MJ, Krueger JG, Carucci JA (2011) The human cutaneous squamous cell carcinoma microenvironment is characterized by increased lymphatic density and enhanced expression of macrophage-derived VEGF-C. J Invest Dermatol 131(1):229-236. doi:10.1038/jid.2010.266
106. Zumsteg A, Baeriswyl V, Imaizumi N, Schwendener R, Ruegg C, Christofori G (2009) Myeloid cells contribute to tumor lymphangiogenesis. PLo S One 4(9):e7067. doi:10.1371/journal. pone.0007067
107. Zhang BC, Gao J, Wang J, Rao ZG, Wang BC, Gao JF (2010) Tumor-associated macrophages infiltration is associated with peritumoral lymphangiogenesis and poor prognosis in lung adenocarcinoma. Med Oncol. doi:10.1007/s12032-010-9638-5
108. Kurahara H, Shinchi H, Mataki Y, Maemura K, Noma H, Kubo F, Sakoda M, Ueno S, Natsugoe S, Takao S (2011) Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J Surg Res 167(2):e211-e219. doi:10.1016/j.jss.2009. 05.026
109. Zhang J, Chen L, Xiao M, Wang C, Qin Z (2010) FSP1+ fibroblasts promote skin carcinogenesis by maintaining MCP-1-mediated macrophage infiltration and chronic inflam-mation. Am JPathol 178(1):382-390. doi:10.1016/j.ajpath.2010. 11.017
110. Erez N, Truitt M, Olson P, Arron ST, Hanahan D (2010) Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappa B-dependent manner. Cancer Cell 17(2):135-147. doi:10.1016/ j.ccr.2009.12.041
111. Silzle T, Kreutz M, Dobler MA, Brockhoff G, Knuechel R, Kunz-Schughart LA (2003) Tumor-associated fibroblasts recruit blood monocytes into tumor tissue. Eur J Immunol 33(5): 1311-1320. doi:10.1002/eji.200323057 (Pubitemid 36612030)
112. Liao D, Luo Y, Markowitz D, Xiang R, Reisfeld RA (2009) Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLo S One 4(11):e7965. doi:10.1371/journal.pone.0007965
113. Rama D, Esendagli G, Guc D (2011) Expression ofchemokine-like receptor 1 (CMKLR1) on J744A.1 macrophages co-cultured with fibroblast and/or tumor cells: modeling the influence of microenvironment. Cell Immunol 271(1):134-140. doi:10.1016/ j.cellimm.2011.06.016
114. Sinha P, Clements VK, Ostrand-Rosenberg S (2005) Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res 65(24):11743-11751. doi:10.1158/0008-5472. CAN-05-0045 (Pubitemid 41821736)
115. Doedens AL, Stockmann C, Rubinstein MP, Liao D, Zhang N, De Nardo DG, Coussens LM, Karin M, Goldrath AW, Johnson RS (2010) Macrophage expression ofhypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progres-sion. Cancer Res 70(19):7465-7475. doi:10.1158/0008-5472. CAN-10-1439
116. Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, Wu C, Zheng L (2009) Activated monocytes in peritumoral stroma of hepato-cellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med 206(6):1327-1337. doi: 10.1084/jem.20082173
117. Zhou J, Ding T, Pan W, Zhu LY, Li L, Zheng L (2009) Increased intratumoral regulatory T cells are related to intratu-moral macrophages and poor prognosis in hepatocellular carcinoma patients. Int J Cancer 125(7):1640-1648. doi: 10.1002/ijc.24556
118. Liu J, Zhang N, Li Q, Zhang W, Ke F, Leng Q, Wang H, Chen J (2011) Tumor-associated macrophages recruit CCR6+ regula-tory T cells and promote the development of colorectal cancer via enhancing CCL20 production in mice. PLo S One 6(4):e19495. doi:10.1371/journal.pone
119. Yang S, Wang B, Guan C, Wu B, Cai C, Wang M, Zhang B, Liu T, Yang P (2011) Foxp3+ IL-17+ T cells promote development of cancer-initiating cells in colorectal cancer. J Leukoc Biol 89(1):85-91. doi:10.1189/jlb.0910506
120. Galani IE, Wendel M, Stojanovic A, Jesiak M, Muller MM, Schellack C, Suri-Payer E, Cerwenka A (2010) Regulatory T cells control macrophage accumulation and activation in lym-phoma. Int J Cancer 127(5):1131-1140. doi:10.1002/ijc.25132
121. Haas M, Dimmler A, Hohenberger W, Grabenbauer GG, Niedobitek G, Distel LV (2009) Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia. BMC Gastroenterol 9:65. doi:10.1186/1471-230X-9- 65
122. Wong SC, Puaux AL, Chittezhath M, Shalova I, Kajiji TS, Wang X, Abastado JP, Lam KP, Biswas SK (2010) Macrophage polarization to a unique phenotype driven by B cells. Eur J Immunol 40(8):2296-2307. doi:10.1002/eji.200940288
123. De Nardo DG, Brennan DJ, Rexhapaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirström K, West BL, Coussens LM (2011) Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Dis-covery 1(1):54-67
124. Zheng Y, Cai Z, Wang S, Zhang X, Qian J, Hong S, Li H, Wang M, Yang J, Yi Q (2009) Macrophages are an abundant com-ponent of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood 114(17):3625-3628. doi:10.1182/blood-2009-05-220285
125. Jinushi M, Chiba S, Yoshiyama H, Masutomi K, Kinoshita I, Dosaka-Akita H, Yagita H, Takaoka A, Tahara H (2011) Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses ofcancer stem/initiating cells. Proc Natl Acad Sci US A 108(30):12425-12430. doi:10.1073/pnas.1106645108
126. Zhu P, Baek SH, Bourk EM, Ohgi KA, Garcia-Bassets I, Sanjo H, Akira S, Kotol PF, Glass CK, Rosenfeld MG, Rose DW (2006) Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell 124(3):615-629. doi:10.1016/j.cell.2005.12.032 (Pubitemid 43199445)
127. Shiai F, Wu X, Zhong C, Yu L, Liang XH, Yao J, Blanchard D, Bais C, Peale FV, van Bruggen N, Ho C, Ross J, Tan M, Carano RA, Meng YG, Ferrara N (2007) Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 450(7171):825-831. doi:10.1038/nature06348 (Pubitemid 350231321)
128. Priceman SJ, Sung JL, Shaposhnik Z, Burton JB, Torres-Collado AX, Moughon DL, Johnson M, Lusis AJ, Cohen DA, Iruela-Arispe ML, Wu L (2011) Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor:
129. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JV (2010) Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 28(3):453-459. doi:10.1200/JCO.2009.24.8252
130. Loges S, Schmidt T, Carmeliet P (2010) Mechanisms of resis-tance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer 1(1):12-25. doi:10.1177/1947601909356574
131. Lemmon MA, Schlessinger J (2010) Cell signaling by receptor tyrosinekinases. Cell 141(7):1117-1134. doi:10.1016/j.cell.2010. 06.011
132. Schlessinger J (2000) Cell signaling by receptor tyrosine kina-ses. Cell 103(2):211-225 S0092-8674(00)00114-8[pii]
133. Lapraz F, Rottinger E, Duboc V, Range R, Duloquin L, Walton K, Wu SY, Bradham C, Loza MA, Hibino T, Wilson K, Poustka A, Mc Clay D, Angerer L, Gache C, Lepage T (2006) RTK and TGF-beta signaling pathways genes in the sea urchin genome. Dev Biol 300(1):132-152. doi:10.1016/j.ydbio.2006.08.048 (Pubitemid 44826999)
134. Satou Y, Imai KS, Levine M, Kohara Y, Rokhsar D, Satoh N (2003) A genomewide survey ofdevelopmentally relevant genes in Ciona intestinalis. I. Genes for b HLH transcription factors. Dev Genes Evol 213(5-6):213-221. doi:10.1007/s00427-003-0319-7 (Pubitemid 36833690)
135. Lai C, Lemke G (1991) An extended family ofprotein-tyrosine kinase genes differentially expressed in the vertebrate nervous system. Neuron 6(5):691-704 0896-6273(91)90167-X[pii]
136. O'Bryan JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, Prokop C, Espinosa R 3rd, Le Beau MM, Earp HS, Liu ET (1991) axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol 11(10):5016-5031 (Pubitemid 21895263)
137. Sasaki T, Knyazev PG, Clout NJ, Cheburkin Y, Gohring W, Ullrich A, Timpl R, Hohenester E (2006) Structural basis for Gas6-Axl signalling. EMBO J 25(1):80-87. doi:10.1038/sj. emboj.7600912 (Pubitemid 43077297)
138. Lemke G, Rothlin CV (2008) Immunobiology of the TAM receptors. Nat Rev Immunol 8(5):327-336. doi:10.1038/nri2303 (Pubitemid 351595219)
139. Hafizi S, Dahlback B (2006) Gas6 and protein S. Vitamin K-dependent ligands for the Axl receptor tyrosine kinase sub-family. FEBS J 273(23):5231-5244. doi:10.1111/j.1742-4658. 2006.05529.x (Pubitemid 44772384)
140. Linger RM, Keating AK, Earp HS, Graham DK (2011) Taking aim at Mer and Axl receptor tyrosine kinases as novel thera-peutic targets in solid tumors. Expert Opin Ther Targets 14(10):1073-1090. doi:10.1517/14728222.2010.515980
141. Zhang QK, Boast S, de los Santos K, Begemann M, Goff SP (1996) Transforming activity of retroviral genomes encoding Gag-Axl fusion proteins. J Virol 70(11):8089-8097 (Pubitemid 26339119)
142. Faust M, Ebensperger C, Schulz AS, Schleithoff L, Hameister H, Bartram CR, Janssen JW (1992) The murine ufo receptor: molecular cloning, chromosomal localization and in situ expression analysis. Oncogene 7(7):1287-1293
143. Angelillo-Scherrer A, Burnier L, Flores N, Savi P, De Mol M, Schaeffer P, Herbert JM, Lemke G, Goff SP, Matsushima GK, Earp HS, Vesin C, Hoylaerts MF, Plaisance S, Collen D, Con-way EM, Wehrle-Haller B, Carmeliet P (2005) Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy. J Clin Invest 115(2):237-246. doi:10.1172/JCI22079 (Pubitemid 40385466)
144. Angelillo-Scherrer A, de Frutos P, Aparicio C, Melis E, Savi P, Lupu F, Arnout J, Dewerchin M, Hoylaerts M, Herbert J, Collen D, Dahlback B, Carmeliet P (2001) Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med 7(2):215-221. doi:10.1038/84667 (Pubitemid 32148489)
145. Linger RM, Keating AK, Earp HS, Graham DK (2008) TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res 100:35-83. doi:10.1016/S0065-230X(08)00002-X (Pubitemid 351932179)
146. Bellosta P, Zhang Q, Goff SP, Basilico C (1997) Signaling through the ARK tyrosine kinase receptor protects from apop-tosis in the absence of growth stimulation. Oncogene 15(20): 2387-2397. doi:10.1038/sj.onc.1201419 (Pubitemid 27503525)
147. Bellosta P, Costa M, Lin DA, Basilico C (1995) The receptor tyrosine kinase ARK mediates cell aggregation by homophilic binding. Mol Cell Biol 15(2):614-625
148. Wimmel A, Glitz D, Kraus A, Roeder J, Schuermann M (2001) Axl receptor tyrosine kinase expression in human lung cancer cell lines correlates with cellular adhesion. Eur J Cancer 37(17):2264-2274 S0959-8049(01)00271-4[pii] (Pubitemid 33001299)
149. Neubauer A, Burchert A, Maiwald C, Gruss HJ, Serke S, Huhn D, Wittig B, Liu E (1997) Recent progress on the role of Axl, a receptor tyrosine kinase, in malignant transformation of myeloid leukemias. Leuk Lymphoma 25(1-2):91-96. doi:10.3109/104 28199709042499 (Pubitemid 27165654)
150. Ou WB, Corson JM, Flynn DL, Lu WP, Wise SC, Bueno R, Sugarbaker DJ, Fletcher JA (2011) AXL regulates mesothelioma proliferation and invasiveness. Oncogene 30(14):1643-1652. doi:10.1038/onc.2010.555
151. Avilla E, Guarino V, Visciano C, Liotti F, Svelto M, Krishna-moorthy G, Franco R, Melillo RM (2011) Activation of TYRO3/ AXL tyrosine kinase receptors in thyroid cancer. Cancer Res 71(5):1792-1804. doi:10.1158/0008-5472.CAN-10-2186
152. Pierce A, Bliesner B, Xu M, Nielsen-Preiss S, Lemke G, Tobet S, Wierman ME (2008) Axl and Tyro3 modulate female reproduction by influencing gonadotropin-releasing hormone neuron survival and migration. Mol Endocrinol 22(11): 2481-2495. doi:10.1210/me.2008-0169
153. Scutera S, Fraone T, Musso T, Cappello P, Rossi S, Pierobon D, Orinska Z, Paus R, Bulfone-Paus S, Giovarelli M (2009) Sur-vival and migration of human dendritic cells are regulated by an IFN-alpha-inducible Axl/Gas6 pathway. J Immunol 183(5): 3004-3013. doi:10.4049/jimmunol.0804384
154. Song X, Wang H, Logsdon CD, Rashid A, Fleming JB, Abbruzzese JL, Gomez HF, Evans DB (2011) Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma. Cancer 117(4): 734-743. doi:10.1002/cncr.25483
155. Keating AK, Kim GK, Jones AE, Donson AM, Ware K, Mulcahy JM, Salzberg DB, Foreman NK, Liang X, Thorburn A, Graham DK (2010) Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity. Mol Cancer Ther 9(5):1298-1307. doi:10.1158/1535- 7163.MCT-09-0707
156. Papadakis ES, Cichon MA, Vyas JJ, Patel N, Ghali L, Cerio R, Storey A, O'Toole EA (2010) Axl promotes cutaneous squa-mous cell carcinoma survival through negative regulation of pro-apoptotic Bcl-2 family members. J Invest Dermatol 131(2): 509-517. doi:10.1038/jid.2010.326
157. Ye X, Li Y, Stawicki S, Couto S, Eastham-Anderson J, Kallop D, Weimer R, Wu Y, Pei L (2010) An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene 29(38): 5254-5264
158. Polvi A, Armstrong E, Lai C, Lemke G, Huebner K, Spritz RA, Guida LC, Nicholls RD, Alitalo K (1993) The human TYRO3 gene and pseudogene are located in chromosome 15q14-q25. Gene 134(2):289-293
159. Ohashi K, Mizuno K, Kuma K, Miyata T, Nakamura T (1994) Cloning of the c DNA for a novel receptor tyrosine kinase, Sky, predominantly expressed in brain. Oncogene 9(3):699-705 (Pubitemid 24065907)
160. Fujimoto J, Yamamoto T (1994) Brt, a mouse gene encoding a novel receptor-type protein-tyrosine kinase, is preferentially expressed in the brain. Oncogene 9(3):693-698 (Pubitemid 24065906)
161. Crosier PS, Freeman SA, Orlic D, Bodine DM, Crosier KE (1996) The Dtk receptor tyrosine kinase, which binds protein S, is expressed during hematopoiesis. Exp Hematol 24(2):318-323 (Pubitemid 26093901)
162. Jansa Perez M, Walshe JA, Crosier KE, Crosier PS (1996) Expression of the DTK receptor tyrosine kinase during zebrafish development. Int J Dev Biol Suppl 1:101S-102S
163. Biscardi JS, Denhez F, Buehler GF, Chesnutt DA, Baragona SC, O'Bryan JP, Der CJ, Fiordalisi JJ, Fults DW, Maness PF (1996) Rek, a gene expressed in retina and brain, encodes a receptor tyrosine kinase of the Axl/Tyro3 family. J Biol Chem 271(46): 29049-29059 (Pubitemid 26382611)
164. Mark MR, Scadden DT, Wang Z, Gu Q, Goddard A, Godowski PJ (1994) rse, a novel receptor-type tyrosine kinase with homology to Axl/Ufo, is expressed at high levels in the brain. J Biol Chem 269(14):10720-10728
165. Schulz NT, Paulhiac CI, Lee L, Zhou R (1995) Isolation and expression analysis of tyro3, a murine growth factor receptor tyrosine kinase preferentially expressed in adult brain. Brain Res Mol Brain Res 28(2):273-280 0169328X94002162[pii]
166. Healy AM, Schwartz JJ, Zhu X, Herrick BE, Varnum B, Farber HW (2001) Gas 6 promotes Axl-mediated survival in pulmonary endothelial cells. Am J Physiol Lung Cell Mol Physiol 280(6):L1273-L1281
167. Nakamura YS, Hakeda Y, Takakura N, Kameda T, Hamaguchi I, Miyamoto T, Kakudo S, Nakano T, Kumegawa M, Suda T (1998) Tyro 3 receptor tyrosine kinase and its ligand, Gas6, stimulate the function ofosteoclasts. Stem Cells 16(3):229-238. doi:10.1002/stem.160229 (Pubitemid 28235167)
168. Dai W, Pan H, Hassanain H, Gupta SL, Murphy MJ Jr (1994) Molecular cloning of a novel receptor tyrosine kinase, tif, highly expressed in human ovary and testis. Oncogene 9(3):975-979 (Pubitemid 24065940)
169. Wang H, Chen S, Chen Y, Wu H, Tang H, Xiong W, Ma J, Ge Y, Lu Q, Han D (2007) The role of Tyro 3 subfamily receptors in the regulation of hemostasis and megakaryocytopoiesis. Haematologica 92(5):643-650 (Pubitemid 350144266)
170. Zhong Z, Wang Y, Guo H, Sagare A, Fernandez JA, Bell RD, Barrett TM, Griffin JH, Freeman RS, Zlokovic BV (2010) Protein S protects neurons from excitotoxic injury by activating the TAM receptor Tyro3-phosphatidylinositol 3-kinase-Akt pathway through its sex hormone-binding globulin-like region. J Neurosci 30(46):15521-15534. doi:10.1523/JNEUROSCI. 4437-10.2010
171. Lan Z, Wu H, Li W, Wu S, Lu L, Xu M, Dai W (2000) Transforming activity of receptor tyrosine kinase tyro3 is mediated, at least in part, by the PI3 kinase-signaling pathway. Blood 95(2):633-638 (Pubitemid 30041680)
172. Taylor IC, Roy S, Varmus HE (1995) Overexpression of the Sky receptor tyrosine kinase at the cell surface or in the cytoplasm results in ligand-independent activation. Oncogene 11(12): 2619-2626 (Pubitemid 26023830)
173. Zhu S, Wurdak H, Wang Y, Galkin A, Tao H, Li J, Lyssiotis CA, Yan F, Tu BP, Miraglia L, Walker J, Sun F, Orth A, Schultz PG, Wu X (2009) A genomic screen identifies TYRO3 as a MITF regulator in melanoma. Proc Natl Acad Sci U S A 106(40):17025-17030. doi:10.1073/pnas.0909292106
174. Heiring C, Dahlback B, Muller YA (2004) Ligand recognition and homophilic interactions in Tyro3: structural insights into the Axl/Tyro3 receptor tyrosine kinase family. J Biol Chem 279(8):6952-6958. doi:10.1074/jbc.M311750200 (Pubitemid 38248838)
175. Graham DK, Dawson TL, Mullaney DL, Snodgrass HR, Earp HS (1994) Cloning and m RNA expression analysis of a novel human protooncogene, c-mer. Cell Growth Differ 5(6): 647-657 (Pubitemid 24252329)
176. Jia R, Hanafusa H (1994) The proto-oncogene of v-eyk (v-ryk) is a novel receptor-type protein tyrosine kinase with extracel-lular Ig/GN-III domains. J Biol Chem 269(3):1839-1844 (Pubitemid 24035382)
177. Graham DK, Bowman GW, Dawson TL, Stanford WL, Earp HS, Snodgrass HR (1995) Cloning and developmental expres-sion analysis of the murine c-mer tyrosine kinase. Oncogene 10(12):2349-2359
178. Chen C, Li Q, Darrow AL, Wang Y, Derian CK, Yang J, de Garavilla L, Andrade-Gordon P, Damiano BP (2004) Mer receptor tyrosine kinase signaling participates in platelet func-tion. Arterioscler Thromb Vasc Biol 24(6):1118-1123. doi: 10.1161/01.ATV.0000130662.30537.0801 (Pubitemid 38737840)
179. Ling L, Kung HJ (1995) Mitogenic signals and transforming potential of Nyk, a newly identified neural cell adhesion mole-cule-related receptor tyrosine kinase. Mol Cell Biol 15(12): 6582-6592
180. Lemke G, Lu Q (2003) Macrophage regulation by Tyro 3 family receptors. Curr Opin Immunol 15(1):31-36 S095279150 200016X[pii] (Pubitemid 35454189)
181. Binder MD, Kilpatrick TJ (2009) TAM receptor signalling and demyelination. Neurosignals 17(4):277-287. doi:10.1159/00023 1894
182. Cohen PL, Caricchio R, Abraham V, Camenisch TD, Jennette JC, Roubey RA, Earp HS, Matsushima G, Reap EA (2002) Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. J Exp Med 196(1):135-140 (Pubitemid 34747319)
183. Rothlin CV, Lemke G (2010) TAM receptor signaling and autoimmune disease. Curr Opin Immunol 22(6):740-746. doi: 10.1016/j.coi.2010.10.001
184. Scott RS, Mc Mahon EJ, Pop SM, Reap EA, Caricchio R, Cohen PL, Earp HS, Matsushima GK (2001) Phagocytosis and clear-ance of apoptotic cells is mediated by MER. Nature 411(6834):207-211. doi:10.1038/35075603 (Pubitemid 32455181)
185. Todt JC, Hu B, Curtis JL (2004) The receptor tyrosine kinase Mer TK activates phospholipase C gamma2 during recognition of apoptotic thymocytes by murine macrophages. J Leukoc Biol 75(4):705-713. doi:10.1189/jlb.0903439 (Pubitemid 38405663)
186. Ostergaard E, Duno M, Batbayli M, Vilhelmsen K, Rosenberg T (2011)A novel MERTK deletion is a common founder mutation in the Faroe Islands and is responsible for a high proportion of retinitis pigmentosa cases. Mol Vis 17:1485-1492
187. Wu YM, Robinson DR, Kung HJ (2004) Signal pathways in up-regulation of chemokines by tyrosine kinase MER/NYK in prostate cancer cells. Cancer Res 64(20):7311-7320. doi: 10.1158/0008-5472.CAN-04-0972 (Pubitemid 39372069)
188. Gyorffy B, Lage H (2007) A web-based data warehouse on gene expression in human malignant melanoma. J Invest Dermatol 127(2):394-399. doi:10.1038/sj.jid.5700543 (Pubitemid 46106919)
189. Stitt TN, Conn G, Gore M, Lai C, Bruno J, Radziejewski C, Mattsson K, Fisher J, Gies DR, Jones PF et al (1995) The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell 80(4):661-670 0092-8674(95)90520-0[pii]
190. Varnum BC, Young C, Elliott G, Garcia A, Bartley TD, Fridell YW, Hunt RW, Trail G, Clogston C, Toso RJ et al (1995) Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6. Nature 373(6515):623-626. doi:10.1038/373623a0
191. Nagata K, Ohashi K, Nakano T, Arita H, Zong C, Hanafusa H, Mizuno K (1996) Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases. J Biol Chem 271(47):30022-30027 (Pubitemid 26389640)
192. Godowski PJ, Mark MR, Chen J, Sadick MD, Raab H, Ham-monds RG (1995) Reevaluation of the roles of protein S and Gas6 as ligands for the receptor tyrosine kinase Rse/Tyro 3. Cell 82(3):355-358 0092-8674(95)90424-7[pii]
193. Mark MR, Chen J, Hammonds RG, Sadick M, Godowsk PJ (1996) Characterization of Gas6, a member of the superfamily of G domain-containing proteins, as a ligand for Rse and Axl. J Biol Chem 271(16):9785-9789
194. Prasad D, Rothlin CV, Burrola P, Burstyn-Cohen T, Lu Q, Garcia de Frutos P, Lemke G (2006) TAM receptor function in the retinal pigment epithelium. Mol Cell Neurosci 33(1):96-108. doi:10.1016/j.mcn.2006.06.011 (Pubitemid 44291594)
195. Schneider C, King RM, Philipson L (1988) Genes specifically expressed at growth arrest of mammalian cells. Cell 54(6): 787-793 S0092-8674(88)91065-3[pii]
196. Dahlback B (1991) Protein S and C4b-binding protein: com-ponents involved in the regulation of the protein C anticoagulant system. Thromb Haemost 66(1):49-61
197. Manfioletti G, Brancolini C, Avanzi G, Schneider C (1993) The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade. Mol Cell Biol 13(8):4976-4985 (Pubitemid 23220402)
198. Sather S, Kenyon KD, Lefkowitz JB, Liang X, Varnum BC, Henson PM, Graham DK (2007) A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation. Blood 109(3):1026-1033. doi:10.1182/blood-2006-05-021634 (Pubitemid 46220648)
199. Angelillo-Scherrer A, Burnier L, Lambrechts D, Fish RJ, Tjwa M, Plaisance S, Sugamele R, De Mol M, Martinez-Soria E, Maxwell PH, Lemke G, Goff SP, Matsushima GK, Earp HS, Chanson M, Collen D, Izui S, Schapira M, Conway EM, Carmeliet P (2008) Role of Gas6 in erythropoiesis and anemia in mice. J Clin Invest 118(2):583-596. doi:10.1172/JCI30375 (Pubitemid 351206548)
200. Tjwa M, Bellido-Martin L, Lin Y, Lutgens E, Plaisance S, Bono F, Delesque-Touchard N, Herve C, Moura R, Billiau AD, Aparicio C, Levi M, Daemen M, Dewerchin M, Lupu F, Arnout J, Herbert JM, Waer M, Garcia de Frutos P, Dahlback B, Car-meliet P, Hoylaerts MF, Moons L (2008) Gas6 promotes inflammation by enhancing interactions between endothelial cells, platelets, and leukocytes. Blood 111(8):4096-4105. doi: 10.1182/blood-2007-05-089565
201. Lutgens E, Tjwa M, Garcia de Frutos P, Wijnands E, Beckers L, Dahlback B, Daemen MJ, Carmeliet P, Moons L (2008) Genetic loss of Gas6 induces plaque stability in experimental athero-sclerosis. J Pathol 216(1):55-63. doi:10.1002/path.2381
202. Burnier L, Saller F, Kadi L, Brisset AC, Sugamele R, Baudino L, Bono F, Herbert JM, Carmeliet P, Schapira M, Izui S, Angelillo-Scherrer A (2011) Gas6 deficiency in recipient mice of allogeneic transplantation alleviates hepatic graft-versus-host disease. Blood 115(16):3390-3397. doi:10.1182/blood-2009-02- 206920
203. Llacuna L, Barcena C, Bellido-Martin L, Fernandez L, Stefa-novic M, Mari M, Garcia-Ruiz C, Fernandez-Checa JC, Garcia de Frutos P, Morales A (2010) Growth arrest-specific protein 6 is hepatoprotective against murine ischemia/reperfusion injury. Hepatology 52(4):1371-1379. doi:10.1002/hep.23833
204. Yin JL, Pilmore HL, Yan YQ, Mc Caughan GW, Bishop GA, Hambly BD, Eris JM (2002) Expression of growth arrest-spe-cific gene 6 and its receptors in a rat model of chronic renal transplant rejection. Transplantation 73(4):657-660 (Pubitemid 34193634)
205. Yin JL, Hambly BD, Bao SS, Painter D, Bishop GA, Eris JM (2003) Expression of growth arrest-specific gene 6 and its receptors in dysfunctional human renal allografts. Transpl Int 16(9):681-688. doi:10.1007/s00147-003-0593-3 (Pubitemid 37193298)
206. Loges S, Schmidt T, Tjwa M, van Geyte K, Lievens D, Lutgens E, Vanhoutte D, Borgel D, Plaisance S, Hoylaerts M, Luttun A, Dewerchin M, Jonckx B, Carmeliet P (2010) Malignant cells fuel tumor growth by educating infiltrating leukocytes to pro-duce the mitogen Gas6. Blood 115(11):2264-2273. doi:10.1182/ blood-2009-06-228684
207. Goruppi S, Chiaruttini C, Ruaro ME, Varnum B, Schneider C (2001) Gas6 induces growth, beta-catenin stabilization, and T-cell factor transcriptional activation in contact-inhibited C57 mammary cells. Mol Cell Biol 21(3):902-915. doi:10.1128/ MCB.21.3.902-915.2001 (Pubitemid 32104738)
208. Sainaghi PP, Castello L, Bergamasco L, Galletti M, Bellosta P, Avanzi GC (2005) Gas6 induces proliferation in prostate car-cinoma cell lines expressing the Axl receptor. J Cell Physiol 204(1):36-44. doi:10.1002/jcp.20265 (Pubitemid 40776804)
209. van Ginkel PR, Gee RL, Shearer RL, Subramanian L, Walker TM, Albert DM, Meisner LF, Varnum BC, Polans AS (2004) Expression of the receptor tyrosine kinase Axl promotes ocular melanoma cell survival. Cancer Res 64(1):128-134 (Pubitemid 38114090)
210. Koessler W, Fiebeler A, Willms A, Elaidi T, Klosterhalfen B, Klinge U (2011) Formation of translational risk score based on correlation coefficients as an alternative to Cox regression models for predicting outcome in patients with NSCLC. Theor Biol Med Model 8(1):28. doi:10.1186/1742-4682-8-28
211. Smiley ST, Boyer SN, Heeb MJ, Griffin JH, Grusby MJ (1997) Protein S is inducible by interleukin 4 in T cells and inhibits lymphoid cell procoagulant activity. Proc Natl Acad Sci US A 94(21):11484-11489 (Pubitemid 27451025)
212. Caberoy NB, Zhou Y, Li W (2010) Tubby and tubby-like pro-tein 1 are new Mer TK ligands for phagocytosis. EMBO J 29(23):3898-3910. doi:10.1038/emboj. 2010.265
213. Li W (2011) Eat-me signals: keys to molecular phagocyte biology and "appetite" control. J Cell Physiol. doi:10.1002/jcp. 22815
214. Holland SJ, Pan A, Franci C, Hu Y, Chang B, Li W, Duan M, Torneros A, Yu J, Heckrodt TJ, Zhang J, Ding P, Apatira A, Chua J, Brandt R, Pine P, Goff D, Singh R, Payan DG, Hitoshi Y (2010) R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of meta-static breast cancer. Cancer Res 70(4):1544-1554. doi:10.1158/ 0008-5472.CAN-09-2997
215. Gustafsson A, Martuszewska D, Johansson M, Ekman C, Hafizi S, Ljungberg B, Dahlback B (2009) Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival. Clin Cancer Res 15(14):4742-4749. doi:10.1158/1078-0432.CCR-08-2514
216. Neubauer A, Fiebeler A, Graham DK, O'Bryan JP, Schmidt CA, Barckow P, Serke S, Siegert W, Snodgrass HR, Huhn D et al (1994) Expression of axl, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis. Blood 84(6): 1931-1941 (Pubitemid 24286145)
217. Challier C, Uphoff CC, Janssen JW, Drexler HG (1996) Dif-ferential expression of the ufo/axl oncogene in human leukemia-lymphoma cell lines. Leukemia 10(5):781-787 (Pubitemid 26168394)
218. Hong CC, Lay JD, Huang JS, Cheng AL, Tang JL, Lin MT, Lai GM, Chuang SE (2008) Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Lett 268(2):314-324. doi:10.1016/j.canlet.2008.04.017
219. Rochlitz C, Lohri A, Bacchi M, Schmidt M, Nagel S, Fopp M, Fey MF, Herrmann R, Neubauer A (1999) Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK). Leukemia 13(9):1352-1358 (Pubitemid 29429761)
220. Grosso S, Puissant A, Dufies M, Colosetti P, Jacquel A, Lebri-gand K Barbry P, Deckert M, Cassuto JP, Mari B, Auberger P (2009) Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors. Mol Cancer Ther 8(7): 1924-1933. doi:10.1158/1535-7163.MCT-09-0168
221. Gioia R, Leroy C, Drullion C, Lagarde V, Etienne G, Dulucq S, Lippert E, Roche S, Mahon FX, Pasquet JM (2011) Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells. Blood 118(8):2211-2221. doi:10.1182/blood-2010-10-313692
222. Ghosh AK, Secreto C, Boysen J, Sassoon T, Shanafelt TD, Mukhopadhyay D, Kay NE (2011) The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy. Blood 117(6):1928-1937. doi: 10.1182/blood-2010-09-305649
223. Graham DK, Salzberg DB, Kurtzberg J, Sather S, Matsushima GK, Keating AK, Liang X, Lovell MA, Williams SA, Dawson TL, Schell MJ, Anwar AA, Snodgrass HR, Earp HS (2006) Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia. Clin Cancer Res 12(9):2662-2669. doi:10.1158/1078-0432.CCR-05-2208
224. Linger RM, De Ryckere D, Brandao L, Sawczyn KK, Jacobsen KM, Liang X, Keating AK, Graham DK (2009) Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia. Blood 114(13):2678-2687. doi: 10.1182/blood-2009-03-209247
225. Shiozawa Y, Pedersen EA, Taichman RS (2010) GAS6/Mer axis regulates the homing and survival of the E2A/PBX1-positive B-cell precursor acute lymphoblastic leukemia in the bone marrow niche. Exp Hematol 38(2):132-140. doi:10.1016/j.exphem.2009.11.002
226. Dai W, Pan HQ, Ouyang B, Greenberg JM, Means RT Jr, Li B, Cardie J (1996) Expression of receptor protein tyrosine kinase tif is regulated during leukemia cell differentiation. Leukemia 10(6):978-983 (Pubitemid 26235930)